(CercleFinance.com) – The Lancet has published clinical trial data for aflibercept 8 mg (Eylea™ 8 mg) from the pivotal phase III PULSAR study in neovascular age-related macular degeneration (AMD) and the phase II/III PHOTON study in diabetic macular edema (DME) during the first year of treatment (at week 48).
Aflibercept 8 mg (Eylea™ 8 mg) with extended treatment intervals of 12 or 16 weeks demonstrated non-inferior vision gains compared to single-dose standard-of-care aflibercept 2 mg (Eylea™ 2 mg). fixed 8-week course for patients with neovascular (wet) aflibercept age-related macular degeneration (AMD) and diabetic macular edema (DME) in the first year (at week 48).
Eylea 8 mg is the first medication to show unprecedented durability results, rapid and resilient fluid control, and a safety profile comparable to standard of care Eylea 2 mg/extended dosing intervals.
‘In its clinical trials, Eylea 8 mg showed significant and clinically relevant benefits, allowing patients to achieve lasting disease control. This means providing lasting and unique vision gains with extended treatment intervals, rapid and resilient fluid control and a safety profile comparable to that of Eylea 2 mg,’ said Professor Paolo Lanzetta, Chairman of the Department of Medicine. ophthalmology at the University of Udine, Italy, and member of the clinical trial steering committee.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
